PredictImmune develops pioneering tools for guiding personalised treatment options in immune-mediated diseases such as inflammatory bowel disease (IBD).

Based on world-leading research at Cambridge University, UK, we are developing a simple lab test, using a small blood sample, which accurately identifies patients at diagnosis who are at risk of experiencing severe, relapsing disease. These patients are likely to benefit from early biologic therapy. Physicians, patients and payers all recognize the value of such an approach to the management of inflammatory bowel disease (IBD).
IBD, Healthtech, Lab

Articles about PredictImmune:

💡 You’re a corporate or investor and looking for startups that are innovating in the same market as PredictImmune? We’re happy to assist you with our Startup Sourcing service.